- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Sarah Houlton
Sarah Houlton
International Correspondent
Sarah Houlton is the international correspondent for Pharmaceutical Executive, covering industry and regulatory issues around the world from her base in London. She is a freelance journalist, specializing in the pharmaceutical and chemical industries. Her background is scientific – her PhD in organic synthesis was sponsored by Glaxo, and she also worked for the James Black Foundation as a research chemist. Sarah was the editor-in-chief of Manufacturing Chemist magazine for several years and now writes for a range of industry publications in both Europe and the United States, as well as undertaking technical writing projects on behalf of several laboratory equipment manufacturers. She also writes about her biggest passion - soccer.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
